Cargando…

Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases

Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibroti...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanel, Stefan Cristian, Rivera-Ortega, Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975385/
https://www.ncbi.nlm.nih.gov/pubmed/36873896
http://dx.doi.org/10.3389/fmed.2023.1114722
_version_ 1784898862506311680
author Stanel, Stefan Cristian
Rivera-Ortega, Pilar
author_facet Stanel, Stefan Cristian
Rivera-Ortega, Pilar
author_sort Stanel, Stefan Cristian
collection PubMed
description Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibrotic therapies where appropriate, there is ample opportunity to implement innovative strategies for early diagnosis and monitoring with the goal of improving clinical outcomes. Early diagnosis can be facilitated by standardizing ILD multidisciplinary team (MDT) discussions, implementing machine learning algorithms for chest computed-tomography quantitative analysis and novel magnetic-resonance imaging techniques, as well as measuring blood biomarker signatures and genetic testing for telomere length and identification of deleterious mutations in telomere-related genes and other single-nucleotide polymorphisms (SNPs) linked to pulmonary fibrosis such as rs35705950 in the MUC5B promoter region. Assessing disease progression in the post COVID-19 era also led to a number of advances in home monitoring using digitally-enabled home spirometers, pulse oximeters and other wearable devices. While validation for many of these innovations is still in progress, significant changes to current clinical practice for PF-ILDs can be expected in the near future.
format Online
Article
Text
id pubmed-9975385
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99753852023-03-02 Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases Stanel, Stefan Cristian Rivera-Ortega, Pilar Front Med (Lausanne) Medicine Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibrotic therapies where appropriate, there is ample opportunity to implement innovative strategies for early diagnosis and monitoring with the goal of improving clinical outcomes. Early diagnosis can be facilitated by standardizing ILD multidisciplinary team (MDT) discussions, implementing machine learning algorithms for chest computed-tomography quantitative analysis and novel magnetic-resonance imaging techniques, as well as measuring blood biomarker signatures and genetic testing for telomere length and identification of deleterious mutations in telomere-related genes and other single-nucleotide polymorphisms (SNPs) linked to pulmonary fibrosis such as rs35705950 in the MUC5B promoter region. Assessing disease progression in the post COVID-19 era also led to a number of advances in home monitoring using digitally-enabled home spirometers, pulse oximeters and other wearable devices. While validation for many of these innovations is still in progress, significant changes to current clinical practice for PF-ILDs can be expected in the near future. Frontiers Media S.A. 2023-02-15 /pmc/articles/PMC9975385/ /pubmed/36873896 http://dx.doi.org/10.3389/fmed.2023.1114722 Text en Copyright © 2023 Stanel and Rivera-Ortega. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Stanel, Stefan Cristian
Rivera-Ortega, Pilar
Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases
title Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases
title_full Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases
title_fullStr Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases
title_full_unstemmed Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases
title_short Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases
title_sort present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975385/
https://www.ncbi.nlm.nih.gov/pubmed/36873896
http://dx.doi.org/10.3389/fmed.2023.1114722
work_keys_str_mv AT stanelstefancristian presentandfutureperspectivesinearlydiagnosisandmonitoringforprogressivefibrosinginterstitiallungdiseases
AT riveraortegapilar presentandfutureperspectivesinearlydiagnosisandmonitoringforprogressivefibrosinginterstitiallungdiseases